



NDA 021595/S-008
NDA 021595/S-009

SUPPLEMENT APPROVAL

Allergan, Inc.
Attention: Thiloshini Pillay, B.Sc., M.Bus
Sr. Specialist, Global Regulatory Affairs
2525 Dupont Drive, P.O. Box 19534
Irvine, CA 92623-9534

Dear Ms. Pillay:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 23, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for SANCTURA[®] (trospium chloride). We acknowledge receipt of your amendment dated June 14, 2012. This supplemental new drug application updates the labeling for SANCTURA[®] according to the Physician's Labeling Rule requirements.

We also refer to your sNDA dated and received June 29, 2012, in response to our letter dated June 7, 2012, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for SANCTURA[®]. This information pertains to the risk of central nervous system effects, specifically, somnolence, accidents, and injuries in patients taking trospium chloride. We also acknowledge receipt of your amendment dated July 23, 2012.

The agreed upon changes to the labeling included in our June 7, 2012, letter are as follows:

Under WARNINGS AND PRECAUTIONS section, the following paragraph is added:

Central Nervous System Effects: SANCTURA[®] is associated with anticholinergic central nervous system (CNS) effects (see ADVERSE REACTIONS: Postmarketing Surveillance). A variety of CNS anticholinergic effects have been reported, including dizziness, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how SANCTURA[®] affects them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.

Under **Information for Patients**, the following statement is revised as follows:

Because anticholinergics such as **SANCTURA**[®] may also produce dizziness, drowsiness, or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects have been determined.

Finally, under **Postmarketing Surveillance** subsection, *dizziness* and *confusion* are added to the Central Nervous System category.

We have completed our review of these supplemental applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Nenita Crisostomo, R.N., Regulatory Health Project Manager, at (301) 796-0875.

Sincerely,

{See appended electronic signature page}

Hylton V. Joffe, M.D., M.M.Sc.
Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

HYLTON V JOFFE
07/23/2012